A study to expand access to vemurafenib for patients with BRAFV600 mutation-positive unresectable/recurrent melanoma. - Vemurafenib(Expand Access Program)

ational Cancer Center Hospital East0 个研究点目标入组 10 人开始时间: 2014年11月1日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 10

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•(1)Patients with brain metastases However, they will be eligible if they have only asymptomatic brain metastases treated by surgical resection or stereotaxic radiation therapy and diagnosed by the investigator/subinvestigators as being free of symptoms, with imaging evidence of stable disease. (2)Patients with concurrent malignancies with a disease-free period of less than 2 years, except cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, cervical carcinoma in situ, and metastatic prostate cancer that has increased prostate-specific antigen (PSA) levels but is not clinically diagnosed by imaging (3)Patients who are pregnant or nursing (4)Patients with difficulty taking oral medications (5)Patients who require concomitant use of other anticancer treatments (e.g., chemotherapy, other molecular-targeted agents, radiation therapy, and other investigational or experimental drugs) (6)Patients who have had the following medical conditions within 6 months prior to the first dose of study drug: Myocardial infarction, severe or unstable angina pectoris, symptomatic congestive heart failure, cerebrovascular disease or transient ischemic attack, pulmonary embolism, and inadequately controlled hypertension (7)Patients with a mean corrected QT (QTc) interval of 450 msec or longer at screening (8)Patients with Grade 2 (as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 4.0) or greater arrhythmia (9)Patients with inadequately controlled concurrent medical conditions (e.g., those requiring intravenous antibiotic therapy) (10)Patients who are unable to use acceptable methods of contraception (11)Patients who are, in the opinion of the investigator/subinvestigators, ineligible for participation in the study for any other reason

研究者

发起方

ational Cancer Center Hospital East

相似试验

已完成

2 期

A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersMultiple Myeloma, Neoplasms

NCT01524978Hoffmann-La Roche208

进行中（未招募）

1 期

An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancersPatients with cancers (excluding melanoma and papillary thyroidcancer) harboring BRAF V600 mutations as identified by theroutinely performed mutation analysis assays at each individualparticipating siteMedDRA version: 17.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-004426-10-DEF. Hoffman-La Roche Ltd.500

进行中（未招募）

1 期

EUCTR2011-004426-10-ESF. Hoffman-La Roche Ltd.121

进行中（未招募）

1 期

An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancersPatients with cancers (excluding melanoma and papillary thyroid cancer) harboring BRAF V600 mutations as identified by the routinely performed mutation analysis assays at each individual participating siteMedDRA version: 18.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10008593 Term: Cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 1

EUCTR2011-004426-10-GBF. Hoffman-La Roche Ltd.208

已完成

2 期

A Study of Vemurafenib in Previously Treated Patients With Metastatic MelanomaMalignant Melanoma

NCT00949702Hoffmann-La Roche132